A randomized phase 3 Open label study of Nivolumab vs Temozolomide each in combination with radiation therapy in newly diagnosed adult subjects with unmethylated MGMT glioblastoma (CA209-498)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2016
End Date
March 22, 2022
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
August 1, 2016
End Date
March 22, 2022